Inactive Instrument

Other languages Advaxis, Inc. Nasdaq

Equities

US0076242082

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	Apr. 03
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	Mar. 24
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	Feb. 20
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 06
Top Midday Gainers	Feb. 06
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	Feb. 06
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023	23-10-23
Ayala Pharmaceuticals, Inc. Announces Executive Changes	23-10-20
BioSight Ltd. acquired Ayala Pharmaceuticals, Inc. in a reverse merger transaction.	23-10-17
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors	23-07-05
Ayala Pharmaceuticals, Inc. Updates RINGSIDE Phase 2 Results Featured in Poster Discussion Session At 2023 American Society of Clinical Oncology Annual Meeting	23-06-05
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Ayala Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30
Ayala Pharmaceuticals Announces Continuation of Ringside Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee	23-03-03
Ayala Pharmaceuticals, Inc. Changes Fiscal Year End from October 31 to December 31	23-01-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Advaxis, Inc. Nasdaq

Equities

US0076242082

Other languages

Filters